These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23723346)

  • 1. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI.
    Sander CY; Hooker JM; Catana C; Normandin MD; Alpert NM; Knudsen GM; Vanduffel W; Rosen BR; Mandeville JB
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11169-74. PubMed ID: 23723346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI.
    Sander CY; Hooker JM; Catana C; Rosen BR; Mandeville JB
    Neuropsychopharmacology; 2016 Apr; 41(5):1427-36. PubMed ID: 26388148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D
    Ghazanfari N; van Waarde A; Doorduin J; Sijbesma JWA; Kominia M; Koelewijn M; Attia K; Vállez-García D; Willemsen ATM; Heeres A; Dierckx RAJO; Visser TJ; de Vries EFJ; Elsinga PH
    Mol Pharm; 2022 Jul; 19(7):2287-2298. PubMed ID: 35732005
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
    Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
    Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.
    Abi-Jaoude E; Segura B; Obeso I; Cho SS; Houle S; Lang AE; Rusjan P; Sandor P; Strafella AP
    Hum Brain Mapp; 2015 Jul; 36(7):2592-601. PubMed ID: 25788222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological MRI responses of raclopride in rats: The relationship with D2 receptor occupancy and cataleptic behavior.
    Masaki Y; Kashiwagi Y; Rokugawa T; Ito M; Iimori H; Abe K
    Synapse; 2020 Dec; 74(12):e22180. PubMed ID: 32644234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.
    Tolboom N; Berendse HW; Leysen JE; Yaqub M; van Berckel BN; Schuit RC; Ponsen MM; Bakker E; Hoetjes NJ; Windhorst AD; Carlsson ML; Lammertsma AA; Carlsson A
    Neuropsychopharmacology; 2015 Jan; 40(2):472-9. PubMed ID: 25248987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity and reliability of extrastriatal [
    Svensson JE; Schain M; Plavén-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
    Neuroimage; 2019 Nov; 202():116143. PubMed ID: 31473354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [
    Shin S; Kim S; Seo S; Lee JS; Howes OD; Kim E; Kwon JS
    Transl Psychiatry; 2018 Apr; 8(1):87. PubMed ID: 29686254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.
    Finnema SJ; Halldin C; Bang-Andersen B; Gulyás B; Bundgaard C; Wikström HV; Farde L
    Synapse; 2009 May; 63(5):378-89. PubMed ID: 19173265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of dopamine receptor 2 binding to pain perception in female fibromyalgia patients with and without depression--A [¹¹C] raclopride PET-study.
    Ledermann K; Jenewein J; Sprott H; Hasler G; Schnyder U; Warnock G; Johayem A; Kollias S; Buck A; Martin-Soelch C
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):320-330. PubMed ID: 26708319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety.
    Berry AS; White RL; Furman DJ; Naskolnakorn JR; Shah VD; D'Esposito M; Jagust WJ
    J Neurosci; 2019 Apr; 39(14):2735-2744. PubMed ID: 30737306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
    Arakawa R; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2010 May; 209(4):285-90. PubMed ID: 20349050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separating dopamine D
    Smart K; Gallezot JD; Nabulsi N; Labaree D; Zheng MQ; Huang Y; Carson RE; Hillmer AT; Worhunsky PD
    Neuroimage; 2020 Jul; 214():116762. PubMed ID: 32201327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain.
    Volkow ND; Wang GJ; Logan J; Alexoff D; Fowler JS; Thanos PK; Wong C; Casado V; Ferre S; Tomasi D
    Transl Psychiatry; 2015 Apr; 5(4):e549. PubMed ID: 25871974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.